They found one protein to be upregulated (serin peptidase inhibitor) and eight proteins to be downregulated (A1BG, fetuin-A, apolipoprotein A-IV, haptoglobin, human Zinc-α-2-glycoprotein, retinol-binding protein, superoxide dismutase 1, transferrin) in patients who converted into RRMS as compared to those who remained in the CIS stage [167]. The gene discussed is A1BG; the disease is in situ carcinoma.